Fear of side effects, not cost, keeps 53.6% of US migraine sufferers on the treatment they have
Worry about a new drug's side effects is what would most keep 53.6% of US migraine sufferers on their current treatment, against 31.8% who say what they have works well enough (n=110, September 2026), and a covered once-daily pill that halves migraine days at no extra cost moved only 12.7% to try it.
- Who was asked
- US migraine sufferers, 110 clones, US
- When
- September 2026 (fielded 13 September 2026)
- How
- Predicted responses from Brox clones, each built from a long-form interview with a real person.
- What changed from the obvious question
- The obvious question, "would you switch to a new migraine preventive?", gets a yes with nothing attached. Instead the same offer was restated three times at no extra cost, $40 more and $150 more a month, with a three-month trial as the middle option; the newest-class offer was put as a next-visit decision with four ways to answer it; and the reasons for staying were asked twice, once as why they have stayed so far and once as what would keep them if something new appeared, so the answer is a wall and a slope rather than a yes.
Section 01: What the panel said
- #
53.6%
53.6% of US migraine sufferers say worry about the side effects of something new is what would most keep them on their current treatment if a new one were available; 31.8% say what they have works well enough, 6.4% say their doctor has not suggested changing, 4.5% would switch as soon as something better appeared and 3.6% are unsure what a new drug would cost or whether insurance would cover it.
base 110
- #
12.7%
With their current approach working reasonably well, a once-daily preventive that halves migraine days, covered by insurance at no extra cost, would be tried or switched to by 12.7% (11.8% for a three-month trial, 0.9% outright) while 96 of 110 would stay; at $40 more a month out of pocket 2.7% would try or switch, and at $150 more, 0.9%.
base 110 · contrast
- #
55.5%
Offered one of the newest class of preventives at their next visit, which guidelines now allow first-line without trying older drugs first, 55.5% would ask questions and decide at a later visit, 30.9% would prefer to stay with their current approach, 7.3% would want to try an older, established drug first and 6.4% would ask to start it.
base 110 · contrast
- #
85.5%
Asked how long they would give a new preventive before deciding whether it works, 55.5% say two to three months and 40.9% about one month; asked how long they would stay on one having noticed no improvement yet, 94 of 110 (85.5%) would stop within a month (62.7% at one month, 11.8% at two weeks, 10.9% after a few days) and 14.5% would stay on it longer.
base 110 · caveat
53.6% of US migraine sufferers say worry about the side effects of something new is what would most keep them on their current treatment if a new one were available; 31.8% say what they have works well enough, 6.4% say their doctor has not suggested changing, 4.5% would switch as soon as something better appeared and 3.6% are unsure what a new drug would cost or whether insurance would cover it.
02What is the first thing a launch team should take from this?
Side effects are the wall, not price and not efficacy. Asked what would most keep them on their current migraine treatment if a new one were available, 53.6% of US migraine sufferers named worry about the side effects of something new, 31.8% said what they have works well enough, 6.4% said their doctor had not suggested a change, and 4.5% said nothing would keep them and they would switch as soon as something better appeared (n=110).
The same wall shows up wherever the study touched it. In Ask Brox's own multi-select on what would make them hesitate, side effects were the most-named concern by a distance, ahead of long-term safety and cost, though a list like that is answered generously and we read it as direction only. Forced to choose between a preventive that halves migraines with a daily side effect such as tiredness or brain fog and one that cuts them by a quarter with no noticeable side effects, 106 of 110 took the quarter. And when the study asked how hard five kinds of dissatisfaction would push them to try something new, side effects that are hard to tolerate were a very strong push for 61.8%, while still having too many migraine days was a very strong push for 14.5% (n=110).
03Where does the answer change, and for whom?
It changes with satisfaction, and in the direction a launch team would least want. Among the 69 who are satisfied with how their current approach controls their migraines, side-effect worry and "it works well enough" tie at 43.5% each. Among the 36 who are dissatisfied, 66.7% name side-effect worry and 13.9% say it works well enough. The people with the most reason to move are the most afraid of what a new drug might do.
They are also the ones who move at all. Offered a covered once-daily pill that halves migraine days at no extra cost, 9 of the 36 dissatisfied would try it or switch, against 5 of the 69 satisfied. Offered one of the newest class of preventives at their next visit, 26 of the 36 dissatisfied would ask questions and decide later and 4 would ask to start it, where 46.4% of the satisfied would ask questions and 40.6% would prefer to stay put. The 11 respondents already on a preventive are a small group and read as counts: 7 of 11 say what they have works well enough, and 10 of 11 would stay with it even at no extra cost.
04How much does cost matter, and how long does a new drug get to prove itself?
Cost matters at a much lower level than a $40 co-pay. With their current approach working reasonably well, a once-daily preventive that halves migraine days, covered at no extra cost, would be tried or switched to by 12.7% (n=110). At $40 more a month out of pocket that falls to 2.7%, and at $150 more to 0.9%. Asked separately where a new preventive would start to feel too expensive, 51.8% put the line somewhere between nothing and $25 a month extra (n=110).
The trial window is short. Asked how long they would give a new preventive before deciding whether it works, 55.5% said two to three months and 40.9% said about one month. Asked instead how long they would stay on one having noticed no improvement yet, 94 of 110 would stop within a month: 62.7% at one month, 11.8% at two weeks and 10.9% after a few days (n=110). Format is a smaller barrier than either: at equal efficacy and cost, 83.6% would rather take a daily pill than a monthly self-injection at home (11.8%), and an IV infusion at a clinic would make 47.3% much less willing to try (n=110).
05What would a brand manager do with this?
- Lead on the side-effect profile, not the efficacy number. This is a reading, not the panel's answer, but a panel that trades half the efficacy for no side effects is telling you which page of the label it will read first.
- Plan for the second visit. 55.5% would take the offer away and come back (n=110), and their own online research (43.6%) rivals the doctor (47.3%) as the biggest influence on whether they try something new, so what they find when they search matters as much as what the doctor says.
- Treat any co-pay above roughly $25 a month as a barrier that needs an assistance answer before launch, not after. That is our reading of the cost curve and the threshold question together.
- Win the first month. Most of this panel would stop at a month with no improvement, so time-to-effect expectations and an early check-in are part of the product, not the follow-up.
Section 06: What they said, and the interview line it rests on
“I would most likely stay with my current treatment because I worry about the side effects of something new. Whenever I think about medications, the very first thing that goes through my head is the side effects. I'm especially hesitant about trying newly released drugs because there often aren't long-term studies showing what could happen 10 or 20 years down the line. Unless the condition was life-threatening, I wouldn't be very comfortable switching to a new medication and risking unknown side effects, like weight gain or impacts on my mental health.”
Predicted from this line in the interview
“I don't think I would be very comfortable doing it. I think what would ultimately cause me to change my mind is how serious of the condition I'm dealing with is. If it's something life threatening, I'm going to be much more willing to try it. And also how long the studies have been. Have there been long term studies of the effects of this drug, not just short term?”
“If my doctor prescribed it and told me it could cut my migraine days in half, I would be open to trying it. Like I've said before, if a doctor recommends something that could be better and help fix the problem, it's definitely worth trying. Since it wouldn't cost me anything extra and my insurance covers it, I would try the new medication for three months. If it didn't work out or caused bad side effects, I could always just go back to my current approach, like drinking Coke, taking my usual medication, or just going to sleep.”
Predicted from this line in the interview
“It all depends on what the new drug is. If it's something that's better, it's going to help my illness, then definitely worth trying.”
“I would definitely ask questions and decide at a later visit. Whenever my doctor brings up something new, my first step is always to do my own research so I can be well-informed. I would want to look into any negative side effects and find out how much the new medication would cost me after insurance. I've had migraines in the past and actually preferred acupuncture over medication, so before jumping into a new drug, I'd need to gather all the facts, check credible sources, and then have a follow-up discussion with my doctor to see if it's the right choice for me.”
Predicted from this line in the interview
“When a doctor tells me something new about my health, typically the next thing I would do is I would do some research on my own about that topic so that I could be more informed about it and have a good discussion with my physician regarding that.”
“I would probably give it about a month, so maybe three to four weeks. I pay very close attention to how my body is reacting to things, and if I'm not getting the benefit of the medication by then, I'm going to start asking questions. Like I've said before, if I'm not getting the benefit, what are we doing? I might reach out to my doctor on MyChart and let them know I'm not seeing any improvement. I've stopped medications in the past when they weren't serving me well or were causing lingering issues after two or three weeks. So I wouldn't drag it out for months on end if it's doing absolutely nothing to help my migraines.”
Predicted from this line in the interview
“However, if I'm not seeing the benefit of it, I usually will reach out to them like in the MyChart thing and let them know. And sometimes I just stop the medication. I let them know, but I'm not taking it. If I'm not getting the benefit, like what are we doing?”
Section 07: How much should you trust this?
What we would defend
- That fear of side effects, not cost and not efficacy, is what keeps this panel where it is: 53.6% name it as the main reason they would stay (n=110), it is the top or joint-top reason in every segment of 30 or more we can cut, and the dissatisfied name it most (66.7%, n=36).
- The slope of the cost curve: a $40 monthly co-pay removes most of an already small willingness to try (12.7% to 2.7%, n=110) and it falls in every segment; separately, 51.8% put the too-expensive line at $25 a month extra or less.
- That an offer of a newest-class preventive opens a second conversation rather than a prescription: 55.5% would ask questions and decide at a later visit and 6.4% would ask to start it (n=110), the top answer in every segment.
- That the stated two-to-three-month trial window collapses to a month the moment nothing improves: 94 of 110 would stop within a month, and that share is three-quarters or more in every segment of 30 or more (the lowest is 27 of 35 among those who have ever taken a preventive).
What we would not
- The 12.7% as a market uptake rate for a new preventive. It is stated intent in a scenario that told respondents their current approach was working reasonably well, and 99 of the 110 are not on a preventive today, so this is mostly a decision to start one rather than to switch.
- The guideline change as the cause of anything. Only 6 of 110 reasonings mention guidelines; the panel answered the offer of a newer-class drug, not the policy behind it.
- The 96.4% who chose a quarter reduction with no side effects over a half reduction with daily tiredness or brain fog as anything more than direction. The side-effect option was written heavily and the choice was forced (106 of 110).
- The 93.6% naming side effects as a hesitation, from a multi-select that was answered generously; the single-select 53.6% is the figure we stand behind.
- Anything about the 11 respondents already on a preventive, the 20 using non-drug approaches only, the 19 men or the 10 aged 65 and over, beyond the counts stated.
- The one-month and the two-to-three-month figures as a contradiction within the panel: they come from two differently worded questions with different option sets, one of them added by Ask Brox.
The main limitation
Stated intent from clones of 110 US adults who get migraines, not observed prescribing or adherence. Only 11 of the 110 take a preventive today; for the rest, what they have is acute prescription medication, over-the-counter painkillers or non-drug approaches, so most answers describe starting a preventive rather than switching one. The panel skews female (91 of 110) and aged 30 to 64 (96 of 110), and every split is one of the study's own questions joined by respondent.
Section 08: How was this run?
| Segment | Clones |
|---|---|
| Doctor-diagnosed migraine | 71 |
| Migraine, not formally diagnosed | 39 |
Question wording as fielded
- Do you get migraines?
- In a typical month, on how many days do you have a migraine?
- Which one best describes how you currently manage your migraines?
- How satisfied are you with how well your current approach controls your migraines?
- Have you ever switched or stopped a preventive medication for migraine?
- Think about the last time you considered changing your migraine treatment. What was the single biggest reason?
- Your doctor tells you about a new preventive medication for migraine. In clinical trials it cut the number of migraine days by about half for most people who took it. It is a pill taken once a day, and your current approach is working reasonably well. What would you do? [series: Your insurance covers it, and it would cost you nothing extra each month compared with what you pay now]
- Your doctor tells you about a new preventive medication for migraine. In clinical trials it cut the number of migraine days by about half for most people who took it. It is a pill taken once a day, and your current approach is working reasonably well. What would you do? [series: Your insurance covers part of it, and it would cost you $40 more each month out of pocket than what you pay now]
- Your doctor tells you about a new preventive medication for migraine. In clinical trials it cut the number of migraine days by about half for most people who took it. It is a pill taken once a day, and your current approach is working reasonably well. What would you do? [series: Your insurance covers only a small part of it, and it would cost you $150 more each month out of pocket than what you pay now]
- If two migraine preventive medications worked equally well and cost you the same, which would you rather take?
- New national guidelines from neurologists now say that doctors can prescribe the newest class of migraine preventive medications first, without patients having to try older, cheaper drugs first. If your doctor offered you one of these newer preventive medications at your next visit, what would you do?
- What would most make you stay with your current migraine treatment even if a new one were available?
- If you had to choose one, which preventive medication would you pick?
- How long would you give a new migraine preventive medication before deciding whether it is working for you?
- Who or what has the most influence on whether you would try a new migraine preventive medication?
- If you started a new migraine preventive treatment and noticed no improvement yet, how long would you still be willing to stay on it before stopping?
- At what extra monthly out-of-pocket cost would a new migraine preventive treatment start to feel too expensive for you to seriously consider?
- What concerns, if any, would make you hesitate to start a new migraine preventive treatment?
- Thinking about your current way of managing migraines, which of these best describes why you have stayed with it so far?
- If your current migraine care left you dissatisfied in each of the following ways, how much would that push you to try a new preventive treatment? [series: Side effects are hard to tolerate]
- If your current migraine care left you dissatisfied in each of the following ways, how much would that push you to try a new preventive treatment? [series: You still have too many migraine days]
- If a new migraine preventive treatment came in each of the following formats, how would that affect your willingness to try it? [series: An IV infusion at a clinic]
What was not asked, and why
No drug, brand or pharmaceutical company was named in any question or option, and the study asked Ask Brox not to add any; none appeared. Respondents were not asked which preventive they take, what they pay today or whether they see a neurologist, so the $40 and $150 anchors are relative to an unknown current spend. Ask Brox added seven questions of its own (hesitation concerns, a format-willingness matrix, how long they would stay on a drug with no improvement, a dissatisfaction-push matrix, what they would want to happen first, the extra-cost threshold, and why they have stayed so far); four are quoted as context and all are in the data table.
What changed from the obvious question
The obvious question, "would you switch to a new migraine preventive?", gets a yes with nothing attached. Instead the same offer was restated three times at no extra cost, $40 more and $150 more a month, with a three-month trial as the middle option; the newest-class offer was put as a next-visit decision with four ways to answer it; and the reasons for staying were asked twice, once as why they have stayed so far and once as what would keep them if something new appeared, so the answer is a wall and a slope rather than a yes.
Fielded through Ask Brox on 13 September 2026.
More on Switching treatment or staying put · Pharma & HCP · Healthcare (US) panel
Ask this of your own customers: humans@brox.ai
Related insights
All in this topic-
Switching a stable patient: 59% of US clinicians, mostly dermatologists, keep the current therapy at a 15-point efficacy gain, and a third still do at 30 points
58.6% 58.6% of US clinicians would keep a patient stable for two years on the current therapy when a newer one gets 75 patients in 100 to the treatment goal against 60, with similar safety and the same cost to the patient; 85.8% keep at 65 against 60 and 32.5% still keep at 90 against 60. (base 169)
Read -
Insurance, not clinical doubt, is what holds back 66.1% of US dermatologists from moving moderate eczema patients off topicals and onto a systemic
66.1% 66.1% of US dermatologists say insurance requirements or prior authorization are what most often make them hold off moving an adult with moderate eczema from topicals to a systemic (base 127)
Read -
Medicare Advantage members would stay for their doctors, not a lower price: 12 of 23 name keeping their providers
12 For the Medicare Advantage members on this panel, keeping their own doctors is the one thing that would hold them to their insurer. (base 23)
Read -
Biosimilar substitution: 94.5% of US clinicians, mostly dermatologists, accept a switch they choose, but half object when a pharmacy swaps without contacting them
50% 50.0% of physicians who manage biologics are uncomfortable (1 or 2 of 5) with a pharmacist substituting an interchangeable biosimilar for a stable patient without contacting them first, against 2.7% when they choose the switch and 20.5% when an insurer requires it. (base 146)
Read